Nose-to-brain delivery of temozolomide-loaded PLGA nanoparticles functionalized with anti-EPHA3 for glioblastoma targeting

References

• Attenello FJ, Mukherjee D, Datoo G, et al. (2008). Use of Gliadel (BCNU) wafer in the surgical treatment of malignant glioma: a 10-year institutional experience. Ann Surg Oncol 15:2887–93.
   PubMed Web of Science ®Google Scholar
• Baker S, Wirth M, Statkevich P, et al. (1999). Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res 5:309–17.
   PubMed Web of Science ®Google Scholar
• Bi C, Wang A, Chu Y, et al. (2016). Intranasal delivery of rotigotine to the brain with lactoferrin-modified PEG-PLGA nanoparticles for Parkinson's disease treatment. Int J Nanomed 11:6547–59.
   PubMed Web of Science ®Google Scholar
• Chakravarti A, Erkkinen MG, Nestler U, et al. (2006). Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res 12:4738–46.
   PubMed Web of Science ®Google Scholar
• Combs SE, Wagner J, Bischof M, et al. (2008). Radiochemotherapy in patients with primary glioblastoma comparing two temozolomide dose regimens. Int J Radiat Oncol Biol Phys 71:999–1005.
   PubMed Web of Science ®Google Scholar
• Day BW, Stringer BW, Al-Ejeh F, et al. (2013). EphA3 maintains tumorigenicity and is a therapeutic target in glioblastoma multiforme. Cancer Cell 23:238–48.
   PubMed Web of Science ®Google Scholar
• Djupesland PG. (2013). Nasal drug delivery devices: characteristics and performance in a clinical perspective-a review. Drug Deliv and Transl Res 3:42–62.
   PubMed Web of Science ®Google Scholar
• Drin G, Cottin S, Blanc E, et al. (2003). Studies on the internalization mechanism of cationic cell-penetrating peptides. J Biol Chem 278:31192–201.
   PubMed Web of Science ®Google Scholar
• du Plessis LH, Kotze AF, Junginger HE. (2010). Nasal and rectal delivery of insulin with chitosan and N-trimethyl chitosan chloride. Drug Deliv 17:399–407.
   PubMed Web of Science ®Google Scholar
• Fan K, Jia X, Zhou M, et al. (2018). Ferritin nanocarrier traverses the blood brain barrier and kills glioma. ACS Nano 125:4105–15.
   Web of Science ®Google Scholar
• Gao H. (2016). Progress and perspectives on targeting nanoparticles for brain drug delivery. Acta Pharm Sin B 6:268–86.
   PubMed Web of Science ®Google Scholar
• Gao H, Yang Z, Cao S, et al. (2014). Tumor cells and neovasculature dual targeting delivery for glioblastoma treatment. Biomaterials 35:2374–82.
   PubMed Web of Science ®Google Scholar
• Gartziandia O, Herran E, Pedraz JL, et al. (2015). Chitosan coated nanostructured lipid carriers for brain delivery of proteins by intranasal administration. Colloids Surf B Biointerfaces 134:304–13.
   PubMed Web of Science ®Google Scholar
• Hagenaars N, Mania M, de Jong P, et al. (2010). Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J Control Release 1441:17–24.
   Web of Science ®Google Scholar
• Hua H, Zhang X, Mu H, et al. (2018). RVG29-modified docetaxel-loaded nanoparticles for brain-targeted glioma therapy. Int J Pharm 543:179–89.
   PubMed Web of Science ®Google Scholar
• Huwyler J, Wu D, Pardridge WM. (1996). Brain drug delivery of small molecules using immunoliposomes. Proc Natl Acad Sci USA 93:14164–9.
   PubMed Web of Science ®Google Scholar
• Hwang DW, Son S, Jang J, et al. (2011). A brain-targeted rabies virus glycoprotein-disulfide linked PEI nanocarrier for delivery of neurogenic microRNA. Biomaterials 32:4968–75.
   PubMed Web of Science ®Google Scholar
• Janes PW, Slape CI, Farnsworth RH, et al. (2014). EphA3 biology and cancer. Growth Factors 32:176–89.
   PubMed Web of Science ®Google Scholar
• Khan AR, Liu M, Khan MW, et al. (2017). Progress in brain targeting drug delivery system by nasal route. J Control Release 268:364–89.
   PubMed Web of Science ®Google Scholar
• Kumari S, Ahsan SM, Kumar JM, et al. (2017). Overcoming blood brain barrier with a dual purpose temozolomide loaded lactoferrin nanoparticles for combating glioma (SERP-17-12433). Sci Rep 7:6602.
   PubMed Web of Science ®Google Scholar
• Lee CY, Ooi IH. (2016). Preparation of temozolomide-loaded nanoparticles for glioblastoma multiforme targeting-ideal versus reality. Pharmaceuticals (Basel) 9:54.
   PubMedGoogle Scholar
• Ling Y, Wei K, Zou F, et al. (2012). Temozolomide loaded PLGA-based superparamagnetic nanoparticles for magnetic resonance imaging and treatment of malignant glioma. Int J Pharm 430:266–75.
   PubMed Web of Science ®Google Scholar
• Meng Q, Wang A, Hua H, et al. (2018). Intranasal delivery of Huperzine A to the brain using lactoferrin-conjugated N-trimethylated chitosan surface-modified PLGA nanoparticles for treatment of Alzheimer's disease. IJN 13:705–18.
   Web of Science ®Google Scholar
• Ramalho MJ, Sevin E, Gosselet F, et al. (2018). Receptor-mediated PLGA nanoparticles for glioblastoma multiforme treatment. Int J Pharm 545:84–92.
   PubMed Web of Science ®Google Scholar
• Ruan S, Yuan M, Zhang L, et al. (2015). Tumor microenvironment sensitive doxorubicin delivery and release to glioma using angiopep-2 decorated gold nanoparticles. Biomaterials 37:425–35.
   PubMed Web of Science ®Google Scholar
• Ruan S, Xiao W, Hu C, et al. (2017). Ligand mediated and enzyme-directed precise targeting and retention for enhanced treatment of glioblastoma. ACS Appl Mater Interfaces 924:20348–60.
   Web of Science ®Google Scholar
• Sharma S, Italiya K, Mittal A, Chitkara D. (2017). New strategies for cancer management how can temozolomide carrier modifications improve its delivery. Therapeutic Delivery 8:475–77.
   PubMed Web of Science ®Google Scholar
• Sheng J, Han L, Qin J, et al. (2015). N-trimethyl chitosan chloride-coated PLGA nanoparticles overcoming multiple barriers to oral insulin absorption. ACS Appl Mater Interfaces 7:15430–41.
   PubMed Web of Science ®Google Scholar
• Song S, Mao G, Du J, et al. (2016). Novel RGD containing, temozolomide-loading nanostructured lipid carriers for glioblastoma multiforme chemotherapy. Drug Deliv 23:1404–08.
   PubMed Web of Science ®Google Scholar
• Swords RT, Greenberg PL, Wei AH, et al. (2016). KB004, a first in class monoclonal antibody targeting the receptor tyrosine kinase EphA3, in patients with advanced hematologic malignancies: results from a phase 1 study. Leuk Res 50:123–31.
   PubMed Web of Science ®Google Scholar
• Trinh VA, Patel SP, Hwu W-J. (2009). The safety of temozolomide in the treatment of malignancies. Expert Opin Drug Saf 8:493–99.
   PubMed Web of Science ®Google Scholar
• Vail ME, Murone C, Tan A, et al. (2014). Targeting EphA3 inhibits cancer growth by disrupting the tumor stromal microenvironment. Cancer Res 74:4470–81.
   PubMed Web of Science ®Google Scholar
• Wang Y. (2009). Pharmaceutical composition containing temozolomide ester. EP, US7579336.
   Google Scholar
• Yung WK, Albright RE, Olson J, et al. (2000). A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer 83:588–93.
   PubMed Web of Science ®Google Scholar
• Zhang H, Gao S. (2007). Temozolomide/PLGA microparticles and antitumor activity against glioma C6 cancer cells in vitro. Int J Pharm 329:122–28.
   PubMed Web of Science ®Google Scholar